ClinicalTrials.gg
CompletedNCT03293030Updated Nov 14, 2025Results posted

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

A Phase 4 interventional study of Dupilumab in Atopic Dermatitis, Atopic Dermatitis Eczema and Eczema, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-14.

Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
43rd of 50
17 · median 75
Started
2018
with 4 others
Phase 4
24 of 50
4 open now
Registered
19th of 50
by date
Lead sponsor
3 of 50
University of California, San Francisco

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 43rd largest by enrollment, is one of 5 that started in 2018, is one of 24 in phase 4, and was the 19th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.

Read the detailed description

Fifteen subjects with moderate to severe AD will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 50). Biopsy samples from AD subjects and surgical discard samples will undergo molecular profiling. Skin swabs and stool samples will be collected and banked for future analysis. The reason to treat patients for 52 weeks is to have the ability to correlate early molecular events with clinical outcomes at week 52.

03

Conditions studied

  • Atopic Dermatitis
  • Atopic Dermatitis Eczema
  • Eczema
  • Atopic Dermatitis and Related Conditions

Keywords

  • atopic dermatitis
  • eczema
  • dupilumab
  • atopic eczema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide written and comply with the protocol.
  • At least 18 years of age.
  • Diagnosis of chronic atopic dermatitis for at least 3 years prior to enrollment.
  • Subject is considered a candidate for phototherapy or systemic therapy
  • Eczema Area and Severity Index (EASI) score ≥ 12
  • Investigator Global Assessment (IGA) ≥ 3
  • 10% body surface area (BSA) or greater
  • Subject is unlikely to conceive due to male, , or using adequate (barrier, hormonal, implant, or permanent sterilization methods).
  • Physical exam within clinically acceptable limits.

Exclusion criteria

Exclusion Criteria:

  • Subject is unable to provide written or comply with the protocol.
  • Subject is younger than 18 years of age.
  • Subject has had atopic dermatitis for less than 3 years prior to enrollment.
  • Subject with mild atopic dermatitis (EASI\<12 and IGA\<3) or is not a candidate for phototherapy or systemic treatments.
  • Subject with current, or a history of, severe atopic dermatitis well controlled on current therapy.
  • Serious known infection.
  • History of (including (HIV))
  • History of within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non- squamous or basal cell carcinoma of the skin.
  • Severe concomitant illnesses.
  • Having used immunosuppressive/immunomodulating drugs (eg, systemic , cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.) or phototherapy within 4 weeks before the baseline visit.
  • Treatment with topical corticosteroid or topical calcineurin inhibitor within 1 week before the baseline visit.
  • Treatment with any cell-depleting agents including but not limited to rituximab: within 6 months before the baseline visit, or until lymphocyte count returns to normal, whichever is longer, or use of other biologics: within 5 half-lives (if known) or 16 weeks prior to baseline visit, whichever is longer.
  • Physical or laboratory exam not within clinically acceptable limits.
  • Subjects possess other diagnoses that, in the investigator's opinion, preclude him/her from safely participating in this study or interfere with the evaluation of the subject's atopic dermatitis.
  • History of known or suspected intolerance to any of the ingredients of the study product.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>10 mIU/mL).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Dupilumab treatment

    15 subjects will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 50). All subjects will undergo skin biopsies for molecular profiling.

    Drug: Dupilumab

Interventions

  • Dupilumab treatment

    Also known as: Dupixent

06

What researchers measure

Primary outcomes

  1. Percent Change in CD4+ T Effector Cells Expressing IL4 in Dupilumab-treated Subjects at Week 12 vs Week 0

    The percent change in CD4+ T effector cells expressing IL-4 in dupilumab-treated subjects at week 12 vs week 0 was calculated as follows. A single value was derived for the entire population with pooled samples from pre- and post-intervention time points, which was then used to calculate a percent change between the two periods. Specifically, the mean M1 across subjects of the percentage of CD4+ T effector cells expressing IL4 was computed at week 0. The mean M2 across subjects of the percentage of CD4+ T effector cells expressing IL4 was computed at week 12. The final result was calculated as: (M1-M2)/M1\*100. Therefore, the result is a number and there is no central tendency metric.

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Differentially Expressed Genes in Cutaneous CD4+ T Cells Between Week 0 and Week 12 in Dupilumab-treated Subjects

    A single value was derived for the entire population with pooled samples from pre- and post-intervention time points, which was then used to calculate an percent change between the two periods. Specifically, single cell RNA-sequencing was used to calculate the number of differentially expressed genes in cutaneous CD4+ T cells between week 0 and week 12 in dupilumab-treated subjects. The calculation was performed in the software package Seurat (RRID:SCR\_016341) using the FindMarkers function, which utilizes a non-parametric Wilcoxon rank-sum test. Genes were considered significantly differentially expressed if the adjusted p-value \< 0.05 and the absolute value of log2(Fold Change) \> 1.0. Therefore, this measure is reported as a number and there is no central tendency metric.

    Time frame: 12 weeks

07

Results

Posted Nov 14, 2025

Participant flow

Participant flow — Overall Study
MilestoneDupilumab Treatment
Started17
Completed14
Not completed3
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryPercent Change in CD4+ T Effector Cells Expressing IL4 in Dupilumab-treated Subjects at Week 12 vs Week 0

The percent change in CD4+ T effector cells expressing IL-4 in dupilumab-treated subjects at week 12 vs week 0 was calculated as follows. A single value was derived for the entire population with pooled samples from pre- and post-intervention time points, which was then used to calculate a percent change between the two periods. Specifically, the mean M1 across subjects of the percentage of CD4+ T effector cells expressing IL4 was computed at week 0. The mean M2 across subjects of the percentage of CD4+ T effector cells expressing IL4 was computed at week 12. The final result was calculated as: (M1-M2)/M1\*100. Therefore, the result is a number and there is no central tendency metric.

Time frame:
12 weeks
Reported as:
Number · Percent change
Percent Change in CD4+ T Effector Cells Expressing IL4 in Dupilumab-treated Subjects at Week 12 vs Week 0
Percent changeDupilumab Treatment
Percent change in lesional skin68.4
Percent change in non-lesional skin100.0
SecondaryNumber of Differentially Expressed Genes in Cutaneous CD4+ T Cells Between Week 0 and Week 12 in Dupilumab-treated Subjects

A single value was derived for the entire population with pooled samples from pre- and post-intervention time points, which was then used to calculate an percent change between the two periods. Specifically, single cell RNA-sequencing was used to calculate the number of differentially expressed genes in cutaneous CD4+ T cells between week 0 and week 12 in dupilumab-treated subjects. The calculation was performed in the software package Seurat (RRID:SCR\_016341) using the FindMarkers function, which utilizes a non-parametric Wilcoxon rank-sum test. Genes were considered significantly differentially expressed if the adjusted p-value \< 0.05 and the absolute value of log2(Fold Change) \> 1.0. Therefore, this measure is reported as a number and there is no central tendency metric.

Time frame:
12 weeks
Reported as:
Number · differentially expressed genes
Number of Differentially Expressed Genes in Cutaneous CD4+ T Cells Between Week 0 and Week 12 in Dupilumab-treated Subjects
differentially expressed genesDupilumab Treatment
DEG in lesional skin81
DEG in non-lesional skin186
Statistical analysis
  • Dupilumab Treatment · Wilcoxon (Mann-Whitney) · p = <0.05 (P-value was adjusted for false discovery rate)

Adverse events

Collected over Through study completion, up to 52 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dupilumab Treatment0/17 (0%)0/17 (0%)10/17 (58.8%)
Most frequent other events
Most frequent other events
EventDupilumab Treatment
Eye irritationEye disorders6/17
Oral/facial herpes simplexInfections and infestations3/17
Deep root cavityMusculoskeletal and connective tissue disorders1/17
migraineNervous system disorders1/17
upper respiratory illness not otherwise definedInfections and infestations1/17
COVID19 (moderate)Infections and infestations1/17
Right ear hearing loss 2/2 Meniere's DiseaseEar and labyrinth disorders1/17
Facial dermatitisSkin and subcutaneous tissue disorders1/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Dupilumab Treatment
<=18 years0
Between 18 and 65 years16
>=65 years1
Age, Continuous
Age, Continuous(years)Dupilumab Treatment
Mean38.1 (21 to 66)
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab Treatment
Female8
Male9
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dupilumab Treatment
Hispanic or Latino1
Not Hispanic or Latino12
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dupilumab Treatment
American Indian or Alaska Native0
Asian10
Native Hawaiian or Other Pacific Islander0
Black or African American0
White3
More than one race0
Unknown or Not Reported4
Region of Enrollment
Region of Enrollment(participants)Dupilumab Treatment
United States17
EASI score
EASI score(units on a scale)Dupilumab Treatment
Mean21.98 (9 to 45.6)
08

Study locations

1 site
  • UCSF Psoriasis and Skin Treatment Center
    San Francisco, California 94118, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Feb 2023, 52 months.

Results were first posted in Nov 2025, 2 years 8 months after primary completion.

Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2017
First posted
Sep 26, 2017
StartActual
Oct 22, 2018
Primary completionActual
Feb 23, 2023
CompletionActual
Feb 23, 2023
Results first posted
Nov 14, 2025
Last update
Nov 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03293030
Responsible party
Sponsor
First posted
Sep 26, 2017
Start date
Oct 22, 2018
Primary completion
Feb 23, 2023
Completion
Feb 23, 2023
Results posted
Nov 14, 2025
Last update
Nov 14, 2025

Study contacts

Wilson Liao, MD
principal investigator · University of California, San Francisco

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion